Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications

被引:47
|
作者
Duque, Alice [1 ]
Mediano, Mauro Felippe Felix [1 ,2 ]
De Lorenzo, Andrea [1 ]
Rodrigues Jr, Luiz Fernando [1 ,3 ]
机构
[1] Inst Nacl Cardiol, Educ & Res Dept, Rua Laranjeiras 374, BR-22240006 Rio De Janeiro, RJ, Brazil
[2] Evandro Chagas Natl Inst Infect Dis, Oswaldo Cruz Fdn, Lab Clin Res Chagas Dis, BR-21040360 Rio De Janeiro, RJ, Brazil
[3] Univ Fed Rio de Janeiro, Inst Biomed, Dept Physiol Sci, BR-22240006 Rio De Janeiro, RJ, Brazil
关键词
Cardiovascular autonomic neuropathy; Cardiac autonomic neuropathy; Diabetes mellitus; Heart rate variability; Sympathetic autonomic nervous system; Parasympathetic autonomic nervous system; HEART-RATE-VARIABILITY; RISK-FACTORS; CARDIAC DENERVATION; OXIDATIVE STRESS; NERVOUS-SYSTEM; QT INTERVAL; MORTALITY; DIAGNOSIS; DYSFUNCTION; IMPACT;
D O I
10.4239/wjd.v12.i6.855
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular autonomic neuropathy (CAN) is a debilitating condition that mainly occurs in long-standing type 2 diabetes patients but can manifest earlier, even before diabetes is diagnosed. CAN is a microvascular complication that results from lesions of the sympathetic and parasympathetic nerve fibers, which innervate the heart and blood vessels and promote alterations in cardiovascular autonomic control. The entire mechanism is still not elucidated, but several aspects of the pathophysiology of CAN have already been described, such as the production of advanced glycation end products, reactive oxygen species, nuclear factor kappa B, and pro-inflammatory cytokines. This microvascular complication is an important risk factor for silent myocardial ischemia, chronic kidney disease, myocardial dysfunction, major cardiovascular events, cardiac arrhythmias, and sudden death. It has also been suggested that, compared to other traditional cardiovascular risk factors, CAN progression may have a greater impact on cardiovascular disease development. However, CAN might be subclinical for several years, and a late diagnosis increases the mortality risk. The duration of the transition period from the subclinical to clinical stage remains unknown, but the progression of CAN is associated with a poor prognosis. Several tests can be used for CAN diagnosis, such as heart rate variability (HRV), cardiovascular autonomic reflex tests, and myocardial scintigraphy. Currently, it has already been described that CAN could be detected even during the subclinical stage through a reduction in HRV, which is a non-invasive test with a lower operating cost. Therefore, considering that diabetes mellitus is a global epidemic and that diabetic neuropathy is the most common chronic complication of diabetes, the early identification and treatment of CAN could be a key point to mitigate the morbidity and mortality associated with this long-lasting condition.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management
    Spallone, Vincenza
    Ziegler, Dan
    Freeman, Roy
    Bernardi, Luciano
    Frontoni, Simona
    Pop-Busui, Rodica
    Stevens, Martin
    Kempler, Peter
    Hilsted, Jannik
    Tesfaye, Solomon
    Low, Phillip
    Valensi, Paul
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2011, 27 (07) : 639 - 653
  • [2] Diabetic cardiovascular autonomic neuropathy: clinical implications
    Karayannis, Georgios
    Giamouzis, Gregory
    Cokkinos, Dennis V.
    Skoularigis, John
    Triposkiadis, Filippos
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2012, 10 (06) : 747 - 765
  • [3] CARDIOVASCULAR AUTONOMIC NEUROPATHY IN DIABETES
    GARCIA, JAV
    LUIS, AS
    MEDICINA CLINICA, 1990, 95 (11): : 417 - 418
  • [4] ASSESSMENT OF CARDIOVASCULAR EFFECTS IN DIABETIC AUTONOMIC NEUROPATHY AND PROGNOSTIC IMPLICATIONS
    EWING, DJ
    CAMPBELL, IW
    CLARKE, BF
    ANNALS OF INTERNAL MEDICINE, 1980, 92 (02) : 308 - 311
  • [5] Spectrum of autonomic cardiovascular neuropathy in diabetes
    Jacob, G
    Costa, F
    Biaggioni, I
    DIABETES CARE, 2003, 26 (07) : 2174 - 2180
  • [6] Diagnosis of cardiovascular autonomic neuropathy in diabetes
    Spallone, V
    Menzinger, G
    DIABETES, 1997, 46 : S67 - S76
  • [7] Assessment of cardiovascular autonomic neuropathy in diabetes by arterial baroreflex sensitivity test
    Teshima, S
    Ikeda, T
    Ohtahara, K
    Narasaki, K
    Ochi, H
    Fujiyama, K
    Tanaka, Y
    Shigemasa, C
    DIABETES, 1996, 45 : 773 - 773
  • [8] Noninvasive assessment of cardiovascular autonomic neuropathy
    Wang, Siqi
    Randall, David C.
    Knapp, Charles F.
    Nelson, Kevin R.
    Patwardhan, Abhijit R.
    Evans, Joyce M.
    FASEB JOURNAL, 2011, 25
  • [9] Clinical Tools for Peripheral Neuropathy to Exclude Cardiovascular Autonomic Neuropathy in Type 2 Diabetes Mellitus
    Pafili, Kalliopi
    Trypsianis, Grigorios
    Papazoglou, Dimitrios
    Maltezos, Efstratios
    Papanas, Nikolaos
    DIABETES THERAPY, 2020, 11 (04) : 979 - 986
  • [10] Clinical Tools for Peripheral Neuropathy to Exclude Cardiovascular Autonomic Neuropathy in Type 2 Diabetes Mellitus
    Kalliopi Pafili
    Grigorios Trypsianis
    Dimitrios Papazoglou
    Efstratios Maltezos
    Nikolaos Papanas
    Diabetes Therapy, 2020, 11 : 979 - 986